Compare Stocks: HRTX, ACB, EYPT, and PALI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.10 -1.7%	$3.96	$2.56 ▼ $6.36	$274.07M	0.63	1.15 million shs	888,832 shs
EYPT Eyepoint Pharmaceuticals	$3.14 +4.3%	$5.24	$2.93 ▼ $19.11	$259.50M	1.67	3.25 million shs	2.84 million shs
HRTX Heron Therapeutics	$0.38 +4.0%	$0.33	$0.26 ▼ $1.58	$68.73M	1.62	2.80 million shs	1.28 million shs
PALI Palisade Bio	$1.54 +4.1%	$1.84	$1.32 ▼ $2.86	$257.92M	1.61	3.44 million shs	1.82 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	-2.80%	-6.50%	+9.45%	+61.63%	-24.04%
EYPT Eyepoint Pharmaceuticals	-1.95%	-9.34%	-29.18%	-76.92%	-77.13%
HRTX Heron Therapeutics	-7.32%	-4.74%	+14.81%	-23.95%	-72.58%
PALI Palisade Bio	+1.02%	0.00%	-27.80%	-21.69%	-20.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACB Aurora Cannabis	$4.10 -1.7%	$3.96	$2.56 ▼ $6.36	$274.07M	0.63	1.15 million shs	888,832 shs
EYPT Eyepoint Pharmaceuticals	$3.14 +4.3%	$5.24	$2.93 ▼ $19.11	$259.50M	1.67	3.25 million shs	2.84 million shs
HRTX Heron Therapeutics	$0.38 +4.0%	$0.33	$0.26 ▼ $1.58	$68.73M	1.62	2.80 million shs	1.28 million shs
PALI Palisade Bio	$1.54 +4.1%	$1.84	$1.32 ▼ $2.86	$257.92M	1.61	3.44 million shs	1.82 million shs

7 Blue-Chip Stocks to Add To Your Forever Portfolio

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACB Aurora Cannabis	-2.80%	-6.50%	+9.45%	+61.63%	-24.04%
EYPT Eyepoint Pharmaceuticals	-1.95%	-9.34%	-29.18%	-76.92%	-77.13%
HRTX Heron Therapeutics	-7.32%	-4.74%	+14.81%	-23.95%	-72.58%
PALI Palisade Bio	+1.02%	0.00%	-27.80%	-21.69%	-20.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACB Aurora Cannabis	2.00	Hold	N/A	N/A
EYPT Eyepoint Pharmaceuticals	2.27	Hold	$25.70	715.36% Upside
HRTX Heron Therapeutics	2.00	Hold	$2.00	433.33% Upside
PALI Palisade Bio	3.00	Buy	$9.29	504.93% Upside

Current Analyst Ratings Breakdown

Latest HRTX, ACB, EYPT, and PALI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
10/12/2026	PALI Palisade Bio	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
10/8/2026	PALI Palisade Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
10/8/2026	PALI Palisade Bio	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$6.00
10/5/2026	ACB Aurora Cannabis	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Strong-Buy ➝ Hold
10/2/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/23/2026	PALI Palisade Bio	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$7.00
9/16/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/2/2026	EYPT Eyepoint Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy ➝ Hold	$20.00 ➝ $4.00
9/1/2026	EYPT Eyepoint Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
8/26/2026	ACB Aurora Cannabis	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 10/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACB Aurora Cannabis	$314.07M	0.86	$0.67 per share	6.11	$6.27 per share	0.65
EYPT Eyepoint Pharmaceuticals	$31.37M	8.66	N/A	N/A	$3.70 per share	0.85
HRTX Heron Therapeutics	$154.90M	0.46	N/A	N/A	$0.07 per share	5.36
PALI Palisade Bio	$250K	1,070.02	N/A	N/A	$0.87 per share	1.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACB Aurora Cannabis	-$88.13M	-$1.41	N/A	68.25	N/A	-32.26%	4.37%	3.45%	11/4/2026 (Estimated)
EYPT Eyepoint Pharmaceuticals	-$231.96M	-$3.74	N/A	N/A	N/A	-10,994.73%	-135.81%	-108.35%	11/4/2026 (Estimated)
HRTX Heron Therapeutics	-$20.19M	-$0.19	N/A	N/A	N/A	-22.52%	-293.02%	-10.00%	11/3/2026 (Estimated)
PALI Palisade Bio	-$16.78M	-$0.48	N/A	N/A	N/A	N/A	-33.47%	-31.79%	11/9/2026 (Estimated)

Latest HRTX, ACB, EYPT, and PALI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	PALI Palisade Bio	-$0.06	N/A	N/A	N/A	$0.47 million	N/A
11/4/2026	Q2 2027	ACB Aurora Cannabis	-$0.03	N/A	N/A	N/A	$50.68 million	N/A
11/4/2026	Q3 2026	EYPT Eyepoint Pharmaceuticals	-$0.9052	N/A	N/A	N/A	$0.23 million	N/A
11/3/2026	Q3 2026	HRTX Heron Therapeutics	-$0.03	N/A	N/A	N/A	$37.50 million	N/A
8/10/2026	Q2 2026	HRTX Heron Therapeutics	-$0.0050	-$0.03	-$0.0250	-$0.03	$42.19 million	$37.67 million
8/10/2026	Q2 2026	PALI Palisade Bio	-$0.0522	-$0.05	+$0.0022	-$0.05	$0.50 million	$0.50 million
8/5/2026	Q1 2027	ACB Aurora Cannabis	-$0.13	$0.04	+$0.17	-$0.05	$47.45 million	$47.62 million
8/5/2026	Q2 2026	EYPT Eyepoint Pharmaceuticals	-$1.01	-$1.09	-$0.08	-$0.2720	$0.45 million	$0.51 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACB Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
EYPT Eyepoint Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
PALI Palisade Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACB Aurora Cannabis	0.03	5.36	2.80
EYPT Eyepoint Pharmaceuticals	N/A	4.50	4.46
HRTX Heron Therapeutics	24.35	2.49	1.51
PALI Palisade Bio	N/A	24.26	24.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACB Aurora Cannabis	47.63%
EYPT Eyepoint Pharmaceuticals	99.41%
HRTX Heron Therapeutics	80.01%
PALI Palisade Bio	11.79%

Insider Ownership

Company	Insider Ownership
ACB Aurora Cannabis	0.01%
EYPT Eyepoint Pharmaceuticals	5.13%
HRTX Heron Therapeutics	6.10%
PALI Palisade Bio	0.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACB Aurora Cannabis	1,028	65.72 million	65.72 million	Optionable
EYPT Eyepoint Pharmaceuticals	214	86.21 million	81.79 million	Optionable
HRTX Heron Therapeutics	128	189.85 million	178.27 million	Optionable
PALI Palisade Bio	14	174.27 million	174.15 million	Not Optionable

HRTX, ACB, EYPT, and PALI Headlines

Recent News About These Companies

Palisade Bio, Inc. Presents New Clinical, Pharmacokinetic, Pharmacodynamic And Mechanistic Data Strengthening Phase 2 Rationale For PALI-2108 In Ulcerative Colitis And Crohn?s ...

October 13 at 7:27 PM | marketscreener.comM

Palisade Bio's (PALI) "Buy" Rating Reiterated at HC Wainwright

October 13 at 8:05 AM | marketbeat.com

Palisade Bio Presents PALI-2108 Data Supporting Phase 2 Trials In Inflammatory Bowel Disease

October 12 at 12:58 PM | rttnews.com

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s ...

October 12 at 12:58 PM | markets.businessinsider.com

Palisade Bio Presents New Clinical, Pharmacokinetic, Pharmacodynamic and Mechanistic Data Strengthening the Phase 2 Rationale for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at ACG 2026

October 12 at 9:00 AM | globenewswire.com

Palisade Bio (NASDAQ:PALI) Raised to Moderate Buy at Raymond James Financial

October 10, 2026 | marketbeat.com

Raymond James initiates coverage of Palisade Bio with outperform

October 9, 2026 | msn.com

Head to Head Review: Bausch Health Cos (NYSE:BHC) and Palisade Bio (NASDAQ:PALI)

October 4, 2026 | americanbankingnews.com

Palisade Bio, Inc. (NASDAQ:PALI) Stock Has Average Target Price of $9.83 According to Analysts

October 3, 2026 | marketbeat.com

Palisade Bio, Inc. Announces Pali-2108 to Be Featured in Four Presentations At United European Gastroenterology Week 2026

September 30, 2026 | marketscreener.comM

Palisade Bio, Inc. annonce que PALI-2108 fera l’objet de quatre présentations lors de la Semaine de la United European Gastroenterology 2026

September 29, 2026 | zonebourse.comZ

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

September 28, 2026 | finance.yahoo.com

Palisade Bio to Present Early PALI-2108 Clinical and Biomarker Data at UEG Week 2026

September 28, 2026 | quiverquant.comQ

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn's Disease at UEG Week 2026

September 28, 2026 | globenewswire.com

Palisade Bio Advances PALI-2108 Into Phase II for Ulcerative Colitis and Crohn’s

September 27, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Palisade Bio (PALI) and Iovance Biotherapeutics (IOVA)

September 25, 2026 | theglobeandmail.com

Palisade Bio, Inc. Receives Health Canada CTA Clearance For ASCENTRA-UC Global Phase 2 Study Evaluating PALI-2108

September 24, 2026 | marketscreener.comM

Analysts Are Bullish on Top Healthcare Stocks: Viking Therapeutics (VKTX), Palisade Bio (PALI)

September 24, 2026 | theglobeandmail.com

Palisade Bio, Inc. erhält von Health Canada CTA-Zulassung für globale Phase-2-Studie ASCENTRA-UC zur Bewertung von PALI-2108

September 24, 2026 | de.marketscreener.comD

Palisade backs away but others not ‘scarred’ of FSCD

September 24, 2026 | bioworld.comB

Palisade Bio Gets Clearance for Phase 2 Trial of Ulcerative Colitis Treatment in Canada

September 24, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HRTX, ACB, EYPT, and PALI Company Descriptions

Aurora Cannabis NASDAQ:ACB

$4.10 -0.07 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$4.15 +0.05 (+1.32%)

As of 07:59 PM Eastern

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Edmonton, Canada.

Eyepoint Pharmaceuticals NASDAQ:EYPT

$3.14 +0.13 (+4.32%)

Closing price 04:00 PM Eastern

Extended Trading

$3.10 -0.04 (-1.40%)

As of 07:56 PM Eastern

EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Heron Therapeutics NASDAQ:HRTX

$0.38 +0.01 (+4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$0.38 0.00 (-0.13%)

As of 07:30 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Palisade Bio NASDAQ:PALI

$1.54 +0.06 (+4.05%)

Closing price 04:00 PM Eastern

Extended Trading

$1.55 +0.01 (+0.58%)

As of 07:50 PM Eastern

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, ACB, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, ACB, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, ACB, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HRTX, ACB, EYPT, and PALI Company Descriptions

Aurora Cannabis NASDAQ:ACB

Eyepoint Pharmaceuticals NASDAQ:EYPT

Heron Therapeutics NASDAQ:HRTX

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HRTX, ACB, EYPT, and PALI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HRTX, ACB, EYPT, and PALI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HRTX, ACB, EYPT, and PALI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

HRTX, ACB, EYPT, and PALI Company Descriptions

Aurora Cannabis NASDAQ:ACB

Eyepoint Pharmaceuticals NASDAQ:EYPT

Heron Therapeutics NASDAQ:HRTX

Palisade Bio NASDAQ:PALI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools